New pill shows promise for rare blood cancers in early trial
NCT ID NCT05153343
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 20 times
Summary
This early-phase trial tested a new drug, flonoltinib maleate, in 31 people with myeloproliferative neoplasms (MPNs), a group of bone marrow disorders that can lead to serious complications. The main goals were to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body and its early signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM (MPN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital Sichuan University
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.